The Fundamental Case for and Against Exact Sciences Corporation (EXAS)

Exact Sciences Corporation (NASDAQ:EXAS) is an interesting stock at present. Now trading with a market value of 4.40B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. As the day-to-day narrative ebbs and flows for this company, it is more important than ever to step back and get a bird’s eye view of the fundamental reality under the surface of this story.

Exact Sciences Corporation (NASDAQ:EXAS) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For EXAS, the company currently has 39.21 million of cash on the books, which is offset by 176,000 in current liabilities. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 350.26 million in total assets, balanced by 40.74 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Exact Sciences Corporation (EXAS) saw -36.38 million in free cash flow last quarter, representing a quarterly net change in cash of -9.72 million. Perhaps most importantly where cash movements are concerned, the company saw about -33.64 million in net operating cash flow.

Exact Sciences Corporation (NASDAQ:EXAS) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 48.36 million in total revenues. That represents a quarterly year/year change in revenues of 2.26 in sequential terms, the EXAS saw sales decline by 0.37.

But what about the bottom line? After all, that’s what really matters in the end. Exact Sciences Corporation (EXAS) is intriguing when broken down to its core data. The cost of selling goods last quarter was 16.98 million, yielding a gross basic income of 31.38 million. For shareholders, given the total diluted outstanding shares of 110.58 million, this means overall earnings per share of -0.32. Note, this compares with a consensus analyst forecast of -0.37 in earnings per share for its next fiscal quarterly report.

Is Exact Sciences Corporation (NASDAQ:EXAS) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -0.94 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Exact Sciences Corporation.

Previous ArticleNext Article

Related Post

Are Infinity Pharmaceuticals, Inc. (INFI)’s ... Recent insider trends for Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) have caught the attention of investors. Insider data is useful because it can r...
Should You Buy New Residential Investment Corp. (N... New Residential Investment Corp. (NYSE:NRZ) and AvalonBay Communities, Inc. (NYSE:AVB) are the two most active stocks in the REIT - Residential indust...
Urban Outfitters, Inc. (URBN) Gains. Buy Signals A... Urban Outfitters, Inc. (NASDAQ:URBN) gained 8.10% in last session, going up from its prior closing price of $20.00 to $21.62, and has now recorded ral...
Analyzing the Insider Data for Jack in the Box (JA... Recent insider trends for Jack in the Box Inc. (NASDAQ:JACK) have caught the attention of investors. Analysts monitor insider data to understand the s...
Should You Invest in Denbury Resources Inc. (DNR)?... Recent insider trends for Denbury Resources Inc. (NYSE:DNR) have caught the attention of investors. Analysts study insider data to get a sense of sens...